ECSS
NBIX icon

Eurizon Capital SGR SpA’s Neurocrine Biosciences NBIX Stock Holding History

Eurizon Capital SGR SpA’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.48M Buy
50,275
+31,746
+171% +$4.71M 0.02% 352
2026
Q1 		$2.44M Buy
18,529
+9,247
+100% +$1.23M 0.01% 513
2025
Q4 		$1.32M Buy
+9,282
New +$1.34M ﹤0.01% 502

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eurizon Capital SGR SpA's NBIX Position: Q2 2026 in Review

Eurizon Capital SGR SpA increased its Neurocrine Biosciences (NBIX) stake by 171% in Q2 2026, buying an estimated $4.71M and bringing the position to 50,275 shares worth $8.48M. The position accounts for 0.02% of the portfolio, ranked #352.

Eurizon Capital SGR SpA first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Eurizon Capital SGR SpA held 50,275 shares of Neurocrine Biosciences worth $8.48M as of Q2 2026.
  • Eurizon Capital SGR SpA bought 31,746 Neurocrine Biosciences shares in Q2 2026, an estimated $4.71M.
  • Neurocrine Biosciences made up 0.02% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #352 holding.
  • Eurizon Capital SGR SpA first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.